China Injectable Drug Delivery Devices Market Size- By Type of Devices, By Therapeutic Application, By Usage Pattern, By Site of Delivery- Regional Outlook, Competitive Strategies and Segment Forecast to 2032

Description

China Injectable Drug Delivery Devices Market Overview

According to SPER Market Research, the China Injectable Drug Delivery Devices Market is estimated to reach USD 235.46 billion by 2032 with a CAGR of 18.23%.

The delivery and transportation of therapeutic medicine to a patient's body is accomplished using injectable devices. The equipment used to deliver injectable drugs comes in a wide variety, including traditional syringes, needle-free injectors, auto-injectors, and pen injectors. Devices for subcutaneous drug delivery are used to treat a variety of chronic and infectious disorders. In this, the medicinal medications are injected using a syringe into the layer between muscles and tissues. Compared to direct injection into veins, absorption happens more slowly.

The market for injectable drug delivery devices is predicted to grow more rapidly in the near future. It is due to the increase in public awareness and significant financial investments in medical infrastructure.

Impact of COVID-19 on the China Injectable Drug Delivery Devices Market

COVID-19 is a highly contagious illness that mostly affects people's respiratory systems. The covid19 is affecting people all throughout the world. With the exception of the pharmaceutical industry, it has had a negative impact on the operation of every industry. There is an increased need for ventilators, testing supplies, medications, vaccines, and oxygen cylinders compared to before the global pandemic. The demand for injectable devices and other healthcare products increased last year, which led to a boom in the market for injectable medication delivery devices. Every country's government devotes a significant portion of its financial resources to acquiring and producing additional pharmaceuticals and medical supplies. People are becoming immunized all throughout the world. The market for injectable medicine delivery methods is growing as a result.

Scope of the Report:

Report Metric Details

Market size available for years 2019-2032

Base year considered 2021

Forecast period 2022-2032

Segments covered By Type of Devices, By Therapeutic Application, By Usage Pattern, By Site of Delivery

Regions covered North China, Northeast China, East China, South China, Central China, Southwest China, Northwest China.

Companies Covered Baxter, Becton, Dickinson and Company, F. Hoffmann-La Roche AG, Gerresheimer AG, GSK plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd.

China Injectable Drug Delivery Devices Market Segmentation:

By Type of Devices: Based on the Type of Devices, China Injectable Drug Delivery Devices Market is segmented as; Conventional Injection Devices, Self-Injection Devices

By Therapeutic Application: Based on the Therapeutic Application, China Injectable Drug Delivery Devices Market is segmented as; Autoimmune Diseases, Hormonal Disorders, Cancer

By Usage Pattern: Based on the Usage Pattern, China Injectable Drug Delivery Devices Market is segmented as; Curative pattern, Immunization

By Site of Delivery: Based on the By Site of Delivery, China Injectable Drug Delivery Devices Market is segmented as; Intramuscular, Subcutaneous, Intra Dermal

By Region: The China Injectable Drug Delivery Devices Market is divided into seven regions North China, Northeast China, East China, South China, Central China, Southwest China, and Northwest China.

Product Code: MEDE2306

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1 Research data source
- 2.1.1 Secondary data
- 2.1.2 Primary data
- 2.1.3 SPER's internal database
- 2.1.4 Premium insight from KOL's
2.2 Market size estimation
- 2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1 Drivers
- 4.1.2 Restraints
- 4.1.3 Opportunities
- 4.1.4 Challenges
4.2. COVID-19 Impacts of the China Injectable Drug Delivery Devices Market

5. Market variables and outlook

5.1. SWOT analysis
- 5.1.1 Strengths
- 5.1.2 Weaknesses
- 5.1.3 Opportunities
- 5.1.4 Threats
5.2. PESTEL analysis
- 5.2.1 Political landscape
- 5.2.2 Economic landscape
- 5.2.3 Social landscape
- 5.2.4 Technological landscape
- 5.2.5 Environmental landscape
- 5.2.6 Legal landscape
5.3. PORTER'S five forces analysis
- 5.3.1 Bargaining power of suppliers
- 5.3.2 Bargaining power of Buyers
- 5.3.3 Threat of Substitute
- 5.3.4 Threat of new entrant
- 5.3.5 Competitive rivalry
5.4. Heat map analysis

6. Competitive Landscape

6.1 China Injectable Drug Delivery Devices Manufacturing Base Distribution, Sales Area, Product Type
6.2 Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in China Injectable Drug Delivery Devices Market

7. China Injectable Drug Delivery Devices Market, By Type of Devices, 2019-2032 (USD Million)

7.1. Conventional Injection Devices
7.2. Self-Injection Devices

8. China Injectable Drug Delivery Devices Market, By Therapeutic Application, 2019-2032 (USD Million)

8.1. Autoimmune Diseases
8.2. Hormonal Disorders
8.3. Cancer

9. China Injectable Drug Delivery Devices Market, By Usage Pattern, 2019-2032 (USD Million)

9.1. Curative pattern
9.2. Immunization

10. China Injectable Drug Delivery Devices Market, By Site of Delivery, 2019-2032 (USD Million)

10.1. Intramuscular
10.2. Subcutaneous
10.3. Intra Dermal

11. China Injectable Drug Delivery Devices Market, By Region, 2019-2032 (USD Million)

11.1. China Injectable Drug Delivery Devices Market Size and Market Share by Region (2019-2025)
11.2. China Injectable Drug Delivery Devices Market Size and Market Share by Region (2026-2032)
11.3. North China
11.4. Northeast China
11.5. East China
11.6. South China
11.7. Central China
11.8. Southwest China
11.9. Northwest China

12. Company Profiles

12.1. Baxter
- 12.1.1. Company details
- 12.1.2. Financial outlook
- 12.1.3. Product summary
- 12.1.4. Recent developments
12.2. Becton
- 12.2.1. Company details
- 12.2.2. Financial outlook
- 12.2.3. Product summary
- 12.2.4. Recent developments
12.3. Dickinson and Company
- 12.3.1. Company details
- 12.3.2. Financial outlook
- 12.3.3. Product summary
- 12.3.4. Recent developments
12.4. F. Hoffmann-La Roche AG
- 12.4.1. Company details
- 12.4.2. Financial outlook
- 12.4.3. Product summary
- 12.4.4. Recent developments
12.5. Gerresheimer AG
- 12.5.1. Company details
- 12.5.2. Financial outlook
- 12.5.3. Product summary
- 12.5.4. Recent developments
12.6. GSK plc
- 12.6.1. Company details
- 12.6.2. Financial outlook
- 12.6.3. Product summary
- 12.6.4. Recent developments
12.7. Merck & Co. Inc.
- 12.7.1. Company details
- 12.7.2. Financial outlook
- 12.7.3. Product summary
- 12.7.4. Recent developments
12.8. Novartis AG
- 12.8.1. Company details
- 12.8.2. Financial outlook
- 12.8.3. Product summary
- 12.8.4. Recent developments
12.9. Pfizer Inc.
- 12.9.1. Company details
- 12.9.2. Financial outlook
- 12.9.3. Product summary
- 12.9.4. Recent developments
12.10. Sanofi
- 12.10.1. Company details
- 12.10.2. Financial outlook
- 12.10.3. Product summary
- 12.10.4. Recent developments
12.11. Teva Pharmaceutical Industries Ltd
- 12.11.1. Company details
- 12.11.2. Financial outlook
- 12.11.3. Product summary
- 12.11.4. Recent developments